已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes

杜拉鲁肽 医学 2型糖尿病 糖尿病 内分泌学 艾塞那肽
作者
Silva A Arslanian,Tamara S. Hannon,Philip Scott Zeitler,Lily C. Chao,Claudia Boucher‐Berry,Margarita Barrientos Pérez,Élise Bismuth,Sérgio Atala Dib,Jang Ik Cho,David Cox
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:387 (5): 433-443 被引量:169
标识
DOI:10.1056/nejmoa2204601
摘要

BACKGROUND: The incidence of type 2 diabetes mellitus is increasing among youths. Once-weekly treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist, may have efficacy with regard to glycemic control in youths with type 2 diabetes. METHODS: In a double-blind, placebo-controlled, 26-week trial, we randomly assigned participants (10 to <18 years of age; body-mass index [BMI], >85th percentile) being treated with lifestyle modifications alone or with metformin, with or without basal insulin, in a 1:1:1 ratio to receive once-weekly subcutaneous injections of placebo, dulaglutide at a dose of 0.75 mg, or dulaglutide at a dose of 1.5 mg. Participants were then included in a 26-week open-label extension study in which those who had received placebo began receiving dulaglutide at a weekly dose of 0.75 mg. The primary end point was the change from baseline in the glycated hemoglobin level at 26 weeks. Secondary end points included a glycated hemoglobin level of less than 7.0% and changes from baseline in the fasting glucose concentration and BMI. Safety was also assessed. RESULTS: A total of 154 participants underwent randomization. At 26 weeks, the mean glycated hemoglobin level had increased in the placebo group (0.6 percentage points) and had decreased in the dulaglutide groups (-0.6 percentage points in the 0.75-mg group and -0.9 percentage points in the 1.5-mg group, P<0.001 for both comparisons vs. placebo). At 26 weeks, a higher percentage of participants in the pooled dulaglutide groups than in the placebo group had a glycated hemoglobin level of less than 7.0% (51% vs. 14%, P<0.001). The fasting glucose concentration increased in the placebo group (17.1 mg per deciliter) and decreased in the pooled dulaglutide groups (-18.9 mg per deciliter, P<0.001), and there were no between-group differences in the change in BMI. The incidence of gastrointestinal adverse events was higher with dulaglutide therapy than with placebo. The safety profile of dulaglutide was consistent with that reported in adults. CONCLUSIONS: Treatment with dulaglutide at a once-weekly dose of 0.75 mg or 1.5 mg was superior to placebo in improving glycemic control through 26 weeks among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI. (Funded by Eli Lilly; AWARD-PEDS ClinicalTrials.gov number, NCT02963766.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Liu完成签到,获得积分10
1秒前
1秒前
yipmyonphu的应助被hyman采纳,获得10
1秒前
1秒前
天地一浮游完成签到,获得积分10
1秒前
rui完成签到,获得积分10
2秒前
风雅络完成签到 ,获得积分10
2秒前
无限的山水完成签到 ,获得积分0
3秒前
sweet完成签到,获得积分10
3秒前
111完成签到,获得积分10
3秒前
YANG完成签到,获得积分10
4秒前
ranj完成签到,获得积分10
5秒前
wwk完成签到 ,获得积分10
5秒前
弈天完成签到 ,获得积分10
5秒前
annaanna完成签到 ,获得积分10
7秒前
英俊h完成签到,获得积分10
8秒前
huyu完成签到 ,获得积分10
9秒前
张帅奔完成签到,获得积分10
10秒前
拾月完成签到 ,获得积分10
11秒前
11秒前
科研通AI65的应助被科研牛马采纳,获得20
11秒前
Kuroba完成签到,获得积分10
11秒前
12秒前
咖啡豆完成签到 ,获得积分10
12秒前
HongY完成签到,获得积分10
12秒前
星辰大海的应助被William123采纳,获得10
13秒前
开心的紫烟完成签到 ,获得积分10
14秒前
14秒前
阿良完成签到 ,获得积分10
15秒前
15秒前
15秒前
蔚蓝色完成签到 ,获得积分10
15秒前
思源的应助被花花采纳,获得10
16秒前
所所的应助被Kuroba采纳,获得10
16秒前
jkxbb完成签到 ,获得积分10
17秒前
坚定初阳完成签到 ,获得积分10
18秒前
少年发布了新的文献求助12
20秒前
orixero的应助被狗熊岭在逃翠花采纳,获得10
20秒前
刘旦生发布了新的文献求助10
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184764
求助须知:如何正确求助?哪些是违规求助? 9573733
关于积分的说明 21832921
捐赠科研通 7782115
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481067